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Abstract
Human immunodeﬁciency virus (HIV) -infected patients with HIV
RNA loads of < 50 copies/mL were followed-up for a median
(interquartile range) of 30.8 (11.7–32.9) months to study the effect
of residual viraemia (RV) on virological rebound (VR). At baseline,
446 (60.3%) patients had undetectable HIV RNA (group A) and
293 (39.7%) had RV (1–49 HIV RNA copies/mL, group B) by
kinetic PCR. VR occurred in 4 (0.9%) patients in group A and in 12
(4.1%) patients in group B (p 0.007). Time to VR was shorter
among patients of group B (Log-rank test: p 0.003). However, the
proportion of VR was extremely low also among patients with RV.
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The effect of residual viraemia (RV) on virological rebound
(VR) in human immunodeﬁciency virus (HIV) -infected patients
on antiretroviral therapy is still debated. We found that the
rate of VR in patients with viral loads of <50 HIV RNA copies/
mL was very low, and RV was not associated with VR over
1 year of follow up [1]. A limitation of this study was the
relatively short follow up and we hypothesized that an effect of
RV on virological breakthrough would have been seen only
after some years of observation.
More recently, two large studies with a similar rationale and
objective have obtained different results [2,3].
The aim of the present analysis was to reconsider the role
of RV on VR through an extended follow up of all the patients
included in the original study.
Study methods have been reported elsewhere [1]; in brief,
at the San Raffaele Scientiﬁc Institute HIV RNA was quantiﬁed
on the basis of the branched DNA Versant HIV-1 RNA 3.0
Assay (bDNA, Siemens Diagnostics, Terrytown, NY, USA;
limit of quantiﬁcation 50 HIV RNA copies/mL) up to February
2009; since March 2009, all patients have been routinely tested
using the kinetic PCR molecular system (kPCR, Versant HIV-1
RNA kPCR 1.0; Siemens Diagnostics). The kPCR assay gives
three possible outputs: (i) a quantitative result for HIV RNA
values of >37 copies/mL; (ii) a semi-quantitative result for HIV
RNA values between 1 and 37 copies/mL; (iii) a qualitative
result (‘undetectable’) if no signal can be detected.
Patients were included from the original analysis (and then
followed up) if the last four consecutive HIV RNA values were
<50 copies/mL, that is: two consecutive HIV RNA values of
<50 copies/mL as tested by bDNA, followed by two consec-
utive HIV RNA values of <50 copies/mL as tested by kPCR.
Two groups of patients were identiﬁed on the basis of the
ﬁrst two kPCR results: patients with undetectable HIV RNA
conﬁrmed in two consecutive samples (group A) and patients
with RV, deﬁned as an HIV RNA load undetectable in one
sample and not in the other or two HIV RNA values of
between 1 and 49 copies/mL (group B).
The detectability ratio was calculated as the number of HIV
RNA measurements of >50 copies/mL divided by the number
of HIV RNA values available from the start of antiretroviral
therapy to the ﬁrst kPCR test.
In the current analysis, the RV ratio was deﬁned as the ratio
between the number of HIV RNA values of 1–49 copies/mL
observed during follow up and the number of viral loads tested
during follow up. The RV ratio was stratiﬁed according to
deciles.
The primary analysis was the time to VR (Kaplan–Meier
curves, with comparison of groups A and B by the log-rank
test). VR was deﬁned as two consecutive HIV RNA values of
>50 copies/mL after baseline. The proportion of VR between
group A and B was compared by the chi-square test.
Patients who changed any of the antiretroviral drugs in their
regimen during follow up while their HIV RNA load was
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<50 copies/mL were censored (and follow up was interrupted)
at the time of the switch.
The multivariable analysis was performed using the Cox
regression proportional hazard model. The outcome was the
occurrence of VR.
All of the statistical tests were two-sided at the 5% level,
and were performed using SAS Software (release 9.2; SAS
Institute, Cary, NC, USA).
There were 739 eligible patients; at baseline, 446 (60.3%)
had undetectable HIV RNA (group A) and 293 (39.7%) had RV
(1–49 HIV RNA copies/mL, group B). During a median
(interquartile range) follow up of 30.8 (11.7–32.9) months,
122 (27.4%) patients in group A and 81 (27.7%) patients in
group B stopped at least one drug of the baseline regimen
while their HIV RNA was <50 copies/mL.
Virological rebound occurred in 16/739 (2.17%) patients, 4/
446 (0.9%) in group A and 12/293 (4.1%) in group B (p 0.007).
Patients with RV at baseline had a higher probability of VR
(log-rank test: p 0.003, Fig. 1a).
One hundred and sixty-four (36.8%) patients in group A
were able to maintain undetectable HIV RNA throughout the
entire follow up, whereas the remaining 282 (63.2%) had at
least one episode of RV during follow up. Four (1.4%) patients
in group B always had HIV RNA values between 1 and
49 copies/mL, whereas 289 (98.6%) had at least one value of
undetectable HIV RNA during follow up.
All VRs occurred among patients who had at least one
episode of RV during follow up, but none of the four patients
who always had RV during follow up showed VR. Almost all
VRs were observed in patients with an RV ratio of >0.5 during
follow up (Fig. 1b).
In the 16 patients who showed VR, the median (interquartile
range) VL at VR was 165 (73–1141) copies/mL. Resistance
testing at VR was available in 4/16: a wild-type virus was
detected in one case and drug-resistance mutations were found
in the remaining three. Nine out of 16 had changed treatment
after VR, whereas seven were able to attain <50 copies HIV
RNA/mL without changing treatment. All the 16 patients who
showed VR were beyond the ﬁrst-line regimen.
The results of the multivariable analysis are illustrated in
Table 1.
Consistently with more recent studies [2,3], this extended
follow up showed that RV favours VR; in particular, RV confers
roughly a four-fold risk of VR and the risk of VR increases with
increasing episodes of RV during follow up. Nevertheless, and
in contrast with another study [2], the VR rate remained
extremely low, even among patients with RV. These ﬁndings
prompt the question as to whether treatment should be
changed in the presence of RV.
At present, no clinical trial supports a change in the current
antiretroviral regimen in a patient with <50 HIV RNA copies/
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FIG. 1. (a) Time to virological rebound according to study groups. (b)
virological rebound according to the residual viraemia ratio during
follow up, among 579 patients with at least one episode of residual
viraemia during follow up. RV: residual viraemia; pts: patients.
TABLE 1. Risk of virological rebound from ﬁtting a multi-
variate Cox proportional hazard model
Characteristic HR 95% CI p-value
Gender (male versus female) 0.343 0.086–1.361 0.128
Age (<50 years versus ≥50 years) 2.862 0.589–13.898 0.192
IVDU versus UKN/other 1.861 0.318–10.872 0.491
Heterosexual versus UKN/other 1.676 0.293–9.584 0.562
MSM versus UKN/other 4.630 0.751–28.535 0.099
HIV stage C3 (no versus yes) 3.769 0.770–18.459 0.102
Years of ARV (per 5 years longer) 1.262 0.748–2.128 0.383
Duration of last ARV regimen
(per year longer)
0.994 0.674–1.466 0.974
Detectability ratio up to BL 23.693 1.647–340.771 0.020
Nadir CD4+ cell count
(≤200 versus >200 cells/lL)
3.745 1.013–13.841 0.048
BL CD4+ (per 100 cells/lL higher) 1.028 0.845–1.251 0.781
RV (group B) versus ‘undetectable’
(group A) at BL
3.862 1.137–13.116 0.030
NRTI-based versus PI/r-based
regimen at BL
1.356 0.143–12.894 0.791
NNRTI-based versus PI/r-based
regimen at BL
0.633 0.115–3.488 0.600
Unboosted-PI versus PI/r-based
regimen at BL
1.441 0.401–5.180 0.576
ARV, antiretroviral therapy; BL, baseline; HIV, human immunodeﬁciency virus; HR,
hazard ratio; IVDU, intravenous drug user; MSM, men who have sex with men;
NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse
transcriptase inhibitors; PI/r, boosted protease inhibitors; RV, residual viraemia;
UKN, unknown.
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mL and, in general, in a patients with RV the risks of new
untoward effects with a different regimen are likely to be
higher than the risk of VR, at least based upon data from
patients starting their ﬁrst antiretroviral regimen [4,5].
Furthermore, it would be very difﬁcult in a patient with VLs
alternating between RV and maximal viral suppression to
identify ‘the right moment’ to change treatment. It would also
be extremely difﬁcult to decide whether the change should
involve a single drug in the regimen or the entire regimen with
no available data to support the decision.
Treatment intensiﬁcation with a fourth drug is not sup-
ported by available data [6–8].
As the detectability ratio is an index of exposure to viral
replication, it is not surprising that its highest impact is on the
risk of VR. The fact that the risk of VR due to previous
exposure to HIV replication was higher than that due to
presence of RV adds further support to the hypothesis that
patients with RV do not have relevant ongoing replication in
most cases.
Many clinical trials and cohort data have shown that a low
nadir CD4+ cell count is associated with a worse virological
response and so it not surprising that it is also associated with
a higher risk of VR [9–12].
In conclusion, RV favoured VR through almost 3 years of
follow up; however, the rate of this event remained extremely
low, even among patients with RV. The frequency of episodes
of RV had signiﬁcant effect on VR.
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